TOToshifumi Ohkusa

Toshifumi Ohkusa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toshifumi Ohkusa has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of Heat-Killed Bifidobacterium breve B-3, a Postbiotic, on Muscle Mass-Related Parameters in Patients with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial

    by Daisuke Asaoka, Shin Yoshimoto, Noriko Katsumata, Noriyuki Iwabuchi, Naotake Yanagisawa, Toshitaka Odamaki, Jin-Zhong Xiao, Tsutomu Takeda, Shigeo Koido, Toshifumi Ohkusa, et al.

    Background/Objectives: Sarcopenia contributes to frailty and functional decline in older adults; however, effective adjunctive strategies remain limited. Heat-killed Bifidobacterium breve B-3 (B-3HK), a postbiotic, has shown muscle-related effects in preclinical studies; however, clinical evidence in patients with established sarcopenia is scarce. This pilot trial aimed to evaluate these clinical effects. Methods: In this 24-week randomized, double-blind, placebo-controlled trial, adults aged 50–89 years with Asian Working Group for Sarcopenia (AWGS) 2019-defined sarcopenia received B-3HK (2 × 1010 cells/day) or placebo daily. The primary outcome was the change in knee extension strength at week 24. Secondary outcomes included body composition measured using bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), physical performance, Eating Assessment Tool-10 (EAT-10), serum biomarkers, gut microbiota, and safety. Secondary outcomes were exploratory with nominal p-values and no adjustment for multiple comparisons. Results: Fifty participants were randomized, and 49 were included in the full analysis set. Compared with placebo, B-3HK did not significantly improve knee extension strength. Exploratory analyses showed between-group differences favoring B-3HK in the BIA-derived skeletal muscle mass index, limb muscle mass, EAT-10 score, and serum insulin-like growth factor-1 and 25-hydroxyvitamin D levels. These differences were primarily driven by the attenuation of the decline in the placebo group and were not corroborated by DXA-derived indices or functional outcomes. The gut microbiota composition did not differ between groups. No serious adverse events were observed. Conclusions: B-3HK did not improve muscle strength in patients with sarcopenia. Exploratory analyses identified nominal between-group differences in body composition and endocrine outcomes; however, these findings were unadjusted for multiplicity and should be regarded as hypothesis-generating rather than confirmatory evidence of efficacy. These data may help inform the design of future adequately powered trials, but confirmation is required before any therapeutic benefit can be inferred.

    • 1 March 2015
      • Vol. 19  (104) , 169-74

    Dendritic-tumor fusion cells in cancer immunotherapy.

    by Kazuki Takakura, Mikio Kajihara, Zensho Ito, Toshifumi Ohkusa, Jianlin Gong, Shigeo Koido

    A promising area of clinical investigation is the use of cancer immunotherapy to treat cancer patients. Dendritic cells (DCs) operate as professional antigen-presenting cells (APCs) and play a critical role in the induction of antitumor immune responses. Thus, DC-based cancer immunotherapy represents a powerful strategy. One DC-based cancer immunotherapy strategy that has been investigated is the administration of fusion cells generated with DCs and whole tumor cells (DC-tumor fusion cells). The DC-tumor fusion cells can process a broad array of tumor-associated antigens (TAAs), including unidentified molecules, and present them through major histocompatibility complex (MHC) class I and II pathways in the context of co-stimulatory signals. Improving the therapeutic efficacy of DC-tumor fusion cell-based cancer immunotherapy requires increased immunogenicity of DCs and whole tumor cells. We discuss the potential ability of DC-tumor fusion cells to activate antigen-specific T cells and strategies to improve the immunogenicity of DC-tumor fusion cells as anticancer vaccines.


    • 1 January 2015
      • Vol. 35  (1) , 555-62

    Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.

    by Kazuki Takakura, Shigeo Koido, Shin Kan, Kosaku Yoshida, Masako Mori, Yuta Hirano, Zensho Ito, Hiroko Kobayashi, Shinichiro Takami, Yoshihiro Matsumoto, et al.

    Treatment combining dendritic cells (DCs) pulsed with three types of major histocompatibility complex (MHC) class I and II (DC/WT1-I/II)-restricted Wilms' tumor 1 (WT1) peptides with chemotherapy may stabilize disease in pancreatic cancer patients. Laboratory data from seven patients with pancreatic cancer who underwent combined DC/WT1-I/II vaccination and chemotherapy were analyzed. The DC phenotypes and plasma cytokine profiles were analyzed via flow cytometry. The post-treatment neutrophil to lymphocyte (N/L) ratio was a treatment-related prognostic factor for better survival. Moreover, the mean fluorescence intensities (MFIs) of human leukocyte antigen (HLA)-DR and cluster of differentiation (CD)83 on DCs were significantly increased after chemoimmunotherapy. Interestingly, interleukin (IL)-6 level in plasma was significantly increased after chemoimmunotherapy in non-super-responders. An increased N/L ratio, as well as HLA-DR and CD83 MFI levels may be prognostic markers of longer survival in patients with advanced pancreatic cancer who undergo chemoimmunotherapy.


    • 1 November 2014
      • Vol. 34  (11) , 6353-61

    Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.

    by Shigeo Koido, Shin Kan, Kosaku Yoshida, Shinji Yoshizaki, Kazuki Takakura, Yoshihisa Namiki, Shintaro Tsukinaga, Shunichi Odahara, Mikio Kajihara, Masato Okamoto, et al.

    Chemoimmunotherapy has been used to treat intrahepatic cholangiocarcinoma (ICC). However, little is known about the phenomena underlying the immunomodulation of ICC cells elicited by chemoimmunotherapy. Primary ICC cells from a patient with ICC who received gemcitabine followed by 5-fluorouracil (5-FU), both combined with dendritic cells pulsed with Wilms' tumor 1 (WT1) peptides were cultured. ICC cells were treated with gemcitabine, 5-FU or interferon (IFN)-γ in vitro. The phenotype of the ICC cells was examined by flow cytometry and quantitative reverse transcription polymerase chain reaction. Stimulation of the ICC cells with gemcitabine resulted in up-regulation of WT1 mRNA, programmed death receptor ligand-1 (PDL1) and calreticulin. Gemcitabine, 5-FU and IFN-γ induced up-regulation of mucin-1. Moreover, human leukocyte antigen (HLA)-ABC, HLA-DR and PDL1 were extremely up-regulated by IFN-γ. Chemoimmunomodulating agents alter the immunogenicity of ICC cells, resulting in complex clinical efficacy results.


    • 1 September 2014
      • Vol. 34  (9) , 4849-55

    Characterization of non-alcoholic steatohepatitis-derived hepatocellular carcinoma as a human stratification model in mice.

    by Kazuki Takakura, Shigeo Koido, Masato Fujii, Taishi Hashiguchi, Yuichiro Shibazaki, Hiroyuki Yoneyama, Hiroaki Katagi, Mikio Kajihara, Takeyuki Misawa, Sadamu Homma, et al.

    The therapeutic strategy against hepatocellular carcinoma (HCC) is determined by tumor stage and liver function. Improvements of stratification contribute to extending the survival of patients. However, stratification has been attributed little attention in animal models largely due to the lack of suitable models. Herein we showed that the recently-reported, non-alcoholic steatohepatitis-derived HCC model (STAM model) is the first murine model in which the concept of human stratification is applicable by demonstrating the following features: (i) at least 4 detectable tumor nodules; (ii) average tumor growth rate of 150 % from 16 to 20 weeks of age; (iii) no visible metastasis; and (iv) relatively preserved liver function. These observations suggested that HCC in STAM mice is equivalent to stages B to C of the Barcelona Clinic Liver Cancer (BCLC) staging system for humans. Application of the stratification concept to experimental animals will create new avenues to establish pharmacological intervention against HCC.


    • 1 September 2014
      • Vol. 34  (9) , 4869-76

    Immunological assessment of cryotherapy in breast cancer patients.

    by Shigeo Koido, Satoki Kinoshita, Takuji Mogami, Shin Kan, Kazuki Takakura, Masato Okamoto, Sadamu Homma, Toshifumi Ohkusa, Hisao Tajiri, Junta Harada

    In murine studies, cryotherapy has induced antitumor immune responses associated with the rejection of tumors. However, the effects of freezing-induced immunomodulation in breast cancer (BC) patients remain unclear. Ten BC patients were prospectively divided into two groups: 1) cryotherapy followed by surgical excision and 2) surgical excision-alone. The cytokine profiles of plasma and peripheral blood mononuclear cells (PBMCs) were analyzed using flow cytometry following in vitro stimulation with the 30-mer MUC1 peptide. No differences in the percentages of interferon-γ (IFN-γ)-producing cluster of differentiation (CD)4(+) or CD8(+) T cells and the plasma levels of IFN-γ, interleukin-1β (IL-1β), IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, tumor necrosis factor-α (TNF-α) and TNF-β were observed between these 2 groups, and PBMCs were not significantly altered. Alternations to the type 1 and 2 helper cytokine profiles were not detected in vitro in BC patients treated with cryotherapy-alone.


  • Open Access

    Long-Term Alteration of Intestinal Microbiota in Patients with Ulcerative Colitis by Antibiotic Combination Therapy

    by Shigeo Koido, Toshifumi Ohkusa, Takayuki Kajiura, Junko Shinozaki, Manabu Suzuki, Keisuke Saito, Kazuki Takakura, Shintaro Tsukinaga, Shunichi Odahara, Toyokazu Yukawa, et al.

    Previous work has demonstrated that intestinal bacteria, such as Fusobacterium varium (F. varium), contribute to the clinical activity in ulcerative colitis (UC); thus, an antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole (ATM)) against F. varium can induce and maintain UC remission. Therefore, we investigated whether ATM therapy induces a long-term alteration of intestinal microbiota in patients with UC. Patients with UC were enrolled in a multicenter, randomized, double-blind, placebo-controlled study. Biopsy samples at the beginning of the trial and again at 3 months after treatment completion were randomly obtained from 20 patients. The terminal restriction fragment length polymorphism (T-RFLP) in mucosa-associated bacterial components was examined to assess the alteration of the intestinal microbiota. Profile changes of T-RFLP in mucosa-associated bacterial components were found in 10 of 12 patients in the treatment group and in none of 8 in the placebo group. Dice similarity coefficients using the unweighted pair group method with arithmetic averages (Dice-UPGMA) confirmed that the similarity of mucosal microbiota from the descending colon was significantly decreased after the ATM therapy, and this change was maintained for at least 3 months. Moreover, at 3 months after treatment completion, the F. varium/β-actin ratio, examined by real-time PCR using nested PCR products from biopsy samples, was reduced less than 40% in 8 of 12 treated patients, which was higher, but not significantly, than in 4 of 8 patients in the placebo group. Together, these results suggest that ATM therapy induces long-term alterations in the intestinal microbiota of patients with UC, which may be associated, at least in part, with clinical effects of the therapy.


  • Synchronous multiple early gastric cancer diagnosed before treatment ; report of two cases

    by Atsushi Harada, Hiroshi Arakawa, Seita Koyama, Sei Adachi, Zensho Ito, Keisuke Saito, Yoshihiro Matsumoto, Kazuki Takakura, Shintaro Tsukinaga, Shunichi Odahara, et al.

    Recently, synchronous multiple early gastric cancers are being increasingly reported due to the aging of society and development of high-performance endoscopy techniques. We present two cases of synchronous multiple early gastric cancers in which the diagnosis was made before the treatment. In Case 1, three pedunculated lesions measuring approximately 10 mm in diameter and one depressed lesion measuring 20 mm in diameter were detected endoscopically in the gastric antrum, and examination of biopsy specimens revealed the diagnosis of cancer for all the lesions. Laparoscopic subtotal gastrectomy was performed, and histology of the resected tissue revealed intramucosal well-differentiated tubular adenocarcinoma in the three pedunculated lesions and intramucosal poorly differentiated adenocarcinoma in the depressed lesion. In Case 2, two depressed lesions measuring approximately 10 mm in diameter and one pedunculated lesion measuring 3 mm in diameter detected in the gastric body were treated by endoscopic submucosal resection. All the resected lesions were diagnosed histopathologically as intramucosal well-differentiated tubular adenocarcinomas. Histopathological examination revealed evidence of atrophic gastritis with intestinal metaplasia due to H. pylori infection in the background gastric mucosa in both the cases, and the mucin expression phenotype of the gastric cancer was the gastric phenotype in the three pedunculated lesions of Case 1 and the intestinal phenotype in all the three lesions in Case 2. We suggest that the possible presence of synchronous multiple cancerous lesions, e.g., well-differentiated adenocarcinoma located in the atropic gastric mucosa, should be investigated endoscopically in patients diagnosed as having early gastric cancer.